Co-Authors
This is a "connection" page, showing publications co-authored by ELIZABETH A GRIMM and VICTOR PRIETO.
Connection Strength
0.743
-
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35.
Score: 0.098
-
Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006 Aug 15; 119(4):861-6.
Score: 0.073
-
Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res. 2004 Aug 15; 10(16):5531-6.
Score: 0.064
-
Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther. 2003 Jan; 2(1):9-17.
Score: 0.057
-
Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer. 2001 Oct 01; 94(1):54-9.
Score: 0.052
-
A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels. In Vitro Cell Dev Biol Anim. 2001 Mar; 37(3):121-6.
Score: 0.050
-
Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000 Dec; 6(12):4768-75.
Score: 0.049
-
4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7.
Score: 0.036
-
Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.
Score: 0.035
-
Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75.
Score: 0.027
-
Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15.
Score: 0.024
-
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51.
Score: 0.022
-
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5.
Score: 0.021
-
Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84.
Score: 0.021
-
Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8.
Score: 0.020
-
Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8.
Score: 0.019
-
Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32.
Score: 0.019
-
Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80.
Score: 0.018
-
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901.
Score: 0.018
-
Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63.
Score: 0.018